Paradigm Therapeutics
CompanyUnited States
Paradigm Therapeutics develops one asset, in phase 3 (SD-101 in epidermolysis bullosa). Mostly small molecule; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 3
- 0
- Trials
- 1
- Signal
Pipeline
1Topical allantoin therapy promotes wound healing and protects damaged skin.
Phase 3, Small molecule, epidermolysis bullosa
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Signals1
- Similar companies4